Citations (37)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Andrea Haake, Kevin Nguyen, Lauren Friedman, Binu Chakkamparambil & George T Grossberg. (2020) An update on the utility and safety of cholinesterase inhibitors for the treatment of Alzheimer’s disease. Expert Opinion on Drug Safety 19:2, pages 147-157.
Read now
Read now
Gabriel C Léger & Fadi Massoud. (2013) Novel disease-modifying therapeutics for the treatment of Alzheimer’s disease. Expert Review of Clinical Pharmacology 6:4, pages 423-442.
Read now
Read now
Geoffrey A Kerchner, Maria Carmela Tartaglia & Adam L Boxer. (2011) Abhorring the vacuum: use of Alzheimer’s disease medications in frontotemporal dementia. Expert Review of Neurotherapeutics 11:5, pages 709-717.
Read now
Read now
Geoffrey A Kerchner & Adam L Boxer. (2010) Bapineuzumab. Expert Opinion on Biological Therapy 10:7, pages 1121-1130.
Read now
Read now
Tomasz Sobow. (2010) Combination treatments in Alzheimer’s disease: risks and benefits. Expert Review of Neurotherapeutics 10:5, pages 693-702.
Read now
Read now
Articles from other publishers (32)
S. Bendjabeur, C. Bensouici & M. Hazzit. (2023) Study of Chemical Composition, Anticholinesterase and Antioxidant Properties of Essential Oil and Ethanolic Extract from Thymus Numidicus Poiret, an Algerian Endemic Medicinal Plant. Pharmaceutical Chemistry Journal 57:6, pages 858-868.
Crossref
Crossref
Hamieh Goshtasbi, Parvin Samadi Pakchin, Ali Movafeghi, Jaleh Barar, Ana M. Castejon, Hossein Omidian & Yadollah Omidi. (2022) Impacts of oxidants and antioxidants on the emergence and progression of Alzheimer's disease. Neurochemistry International 153, pages 105268.
Crossref
Crossref
Yijing Tang, Dong Zhang, Xiong Gong & Jie Zheng. (2022) A mechanistic survey of Alzheimer's disease. Biophysical Chemistry 281, pages 106735.
Crossref
Crossref
Halit Kantekin, Halise Yalazan, Burak Barut, Ömer Güngör, Dilek Ünlüer, Ümit Demirbaş, Arzu Özel & Mahmut Durmuş. (2021) Dual-purpose both peripheral and non-peripheral triazole substituted ZnII, MgII and PbII phthalocyanines: Synthesis, characterization, photophysicochemical and acetylcholinesterase inhibitory properties. Polyhedron 208, pages 115416.
Crossref
Crossref
Tayfun Arslan. (2021) Design, synthesis of novel peripherally tetra-chalcone substituted phthalocyanines and their inhibitory effects on acetylcholinesterase and carbonic anhydrases (hCA I and II). Journal of Organometallic Chemistry 951, pages 122021.
Crossref
Crossref
Fatemeh Fereidooni, Gholamreza Komeili, Hamed Fanaei, Tahereh Safari, Sadegh Khorrami & Abdurrashid Khazaei Feizabad. (2020) ☆Protective effects of ginseng on memory and learning and prevention of hippocampal oxidative damage in streptozotocin-induced Alzheimer's in a rat model. Neurology, Psychiatry and Brain Research 37, pages 116-122.
Crossref
Crossref
Tayfun Arslan, M. Buğrahan Ceylan, Hüseyin Baş, Zekeriya Biyiklioglu & Murat Senturk. (2020) Design, synthesis, characterization of peripherally tetra-pyridine-triazole-substituted phthalocyanines and their inhibitory effects on cholinesterases (AChE/BChE) and carbonic anhydrases (hCA I, II and IX). Dalton Transactions 49:1, pages 203-209.
Crossref
Crossref
N. M. Zalutskaya, I. A. Beltceva & N. G. Neznanov. (2018) Tolerability of antidementive therapy: results of observational research. V.M. BEKHTEREV REVIEW OF PSYCHIATRY AND MEDICAL PSYCHOLOGY:2, pages 117-124.
Crossref
Crossref
Makbule Ekiz, Ahmet Tutar, Salih Ökten, Burcu Bütün, Ümit M. Koçyiğit, Parham Taslimi & Gülaçtı Topçu. (2018) Synthesis, characterization, and SAR of arylated indenoquinoline-based cholinesterase and carbonic anhydrase inhibitors. Archiv der Pharmazie 351:9, pages 1800167.
Crossref
Crossref
Masood Fereidoonnezhad, Azar Mostoufi, Samaneh Zali, Maryam Eskandari, Davoud Afshar & Fariba Aliyan. (2017) Molecular Docking and PLIF Studies of Novel Tacrine-Naphtoquinone Hybrids Based on Multi-Target-Directed Ligand Approach for Alzheimer’s Disease. Jundishapur Journal of Natural Pharmaceutical Products 13:2.
Crossref
Crossref
Rita Khoury, Kush Patel, Jake Gold, Stephanie Hinds & George T. Grossberg. (2017) Recent Progress in the Pharmacotherapy of Alzheimer’s Disease. Drugs & Aging 34:11, pages 811-820.
Crossref
Crossref
Mohammad Eghtedari, Yaghoub Sarrafi, Hamid Nadri, Mohammad Mahdavi, Alireza Moradi, Farshad Homayouni Moghadam, Saeed Emami, Loghman Firoozpour, Ali Asadipour, Omid Sabzevari & Alireza Foroumadi. (2017) New tacrine-derived AChE/BuChE inhibitors: Synthesis and biological evaluation of 5-amino-2-phenyl-4H-pyrano[2,3-b]quinoline-3-carboxylates. European Journal of Medicinal Chemistry 128, pages 237-246.
Crossref
Crossref
Dan Zhou, Wei Zhou, Jun-ke Song, Zhang-ying Feng, Ran-yao Yang, Song Wu, Lin Wang, Ai-lin Liu & Guan-hua Du. (2016) DL0410, a novel dual cholinesterase inhibitor, protects mouse brains against Aβ-induced neuronal damage via the Akt/JNK signaling pathway. Acta Pharmacologica Sinica 37:11, pages 1401-1412.
Crossref
Crossref
Ayokunle O. Ademosun, Ganiyu Oboh, Fatai Bello & Peluola O. Ayeni. (2016) Antioxidative Properties and Effect of Quercetin and Its Glycosylated Form (Rutin) on Acetylcholinesterase and Butyrylcholinesterase Activities. Journal of Evidence-Based Complementary & Alternative Medicine 21:4, pages NP11-NP17.
Crossref
Crossref
Carole Parsons. (2016) Withdrawal of Antidementia Drugs in Older People: Who, When and How?. Drugs & Aging 33:8, pages 545-556.
Crossref
Crossref
Shaobing Cheng, Wei Zheng, Ping Gong, Qiang Zhou, Qiong Xie, Lining Yu, Peiyi Zhang, Liangkang Chen, Juan Li, Jianxing Chen, Hailin Chen & Hongzhuan Chen. (2015) (−)-Meptazinol–melatonin hybrids as novel dual inhibitors of cholinesterases and amyloid-β aggregation with high antioxidant potency for Alzheimer’s therapy. Bioorganic & Medicinal Chemistry 23:13, pages 3110-3118.
Crossref
Crossref
Sai-Sai Xie, Xiaobing Wang, Neng Jiang, Wenying Yu, Kelvin D.G. Wang, Jin-Shuai Lan, Zhong-Rui Li & Ling-Yi Kong. (2015) Multi-target tacrine-coumarin hybrids: Cholinesterase and monoamine oxidase B inhibition properties against Alzheimer's disease. European Journal of Medicinal Chemistry 95, pages 153-165.
Crossref
Crossref
Chien-Wei Hou, Shun-Yu Chang & Kee-Ching Jeng. (2014) Protective effect of a sesamin derivative, 3-bis (3-methoxybenzyl) butane-1, 4-diol on Aβ-stressed PC12 cells. Archives of Pharmacal Research 38:4, pages 543-548.
Crossref
Crossref
Maria Digiacomo, Ziwei Chen, Shengnan Wang, Annalina Lapucci, Marco Macchia, Xiaohong Yang, Jiaqi Chu, Yifan Han, Rongbiao Pi & Simona Rapposelli. (2015) Synthesis and pharmacological evaluation of multifunctional tacrine derivatives against several disease pathways of AD. Bioorganic & Medicinal Chemistry Letters 25:4, pages 807-810.
Crossref
Crossref
David B Hogan. (2014) Long-Term Efficacy and Toxicity of Cholinesterase Inhibitors in the Treatment of Alzheimer Disease. The Canadian Journal of Psychiatry 59:12, pages 618-623.
Crossref
Crossref
Mauricio Alcolea-Palafox, Paloma Posada-Moreno, Ismael Ortuño-Soriano, José L. Pacheco-del-Cerro, Carmen Martínez-Rincón, Dolores Rodríguez-Martínez & Lara Pacheco-Cuevas. 2014. Drug Design and Discovery in Alzheimer's Disease. Drug Design and Discovery in Alzheimer's Disease
426
477
.
Annalena Venneri & Michael F Shanks. (2013) Central effects of cholinesterase inhibitors in Alzheimer’s disease: insights from advanced neuroimaging. Imaging in Medicine 5:5, pages 441-452.
Crossref
Crossref
Rafael León, Antonio G. Garcia & José Marco‐Contelles. (2011) Recent advances in the multitarget‐directed ligands approach for the treatment of Alzheimer's disease. Medicinal Research Reviews 33:1, pages 139-189.
Crossref
Crossref
María Isabel Fernández-Bachiller, Concepción Pérez, Leticia Monjas, Jörg Rademann & María Isabel Rodríguez-Franco. (2012)
New Tacrine–4-Oxo-4
H
-chromene Hybrids as Multifunctional Agents for the Treatment of Alzheimer’s Disease, with Cholinergic, Antioxidant, and β-Amyloid-Reducing Properties
. Journal of Medicinal Chemistry 55:3, pages 1303-1317.
Crossref
Crossref
Volkmar Tell, Kazem Ahmed Mahmoud, Kanin Wichapong, Christoph Schächtele, Frank Totzke, Wolfgang Sippl & Andreas Hilgeroth. (2012) Novel aspects in structure–activity relationships of profiled 1-aza-9-oxafluorenes as inhibitors of Alzheimer's disease-relevant kinases cdk1, cdk5 and gsk3β. MedChemComm 3:11, pages 1413.
Crossref
Crossref
Denise M. Boudreau, Onchee Yu, Shelly L. Gray, Marsha A. Raebel, Jeanene Johnson & Eric B. Larson. (2011) Concomitant Use of Cholinesterase Inhibitors and Anticholinergics: Prevalence and Outcomes. Journal of the American Geriatrics Society 59:11, pages 2069-2076.
Crossref
Crossref
Stefano Rizzo, Alessandra Bisi, Manuela Bartolini, Francesca Mancini, Federica Belluti, Silvia Gobbi, Vincenza Andrisano & Angela Rampa. (2011) Multi-target strategy to address Alzheimer’s disease: Design, synthesis and biological evaluation of new tacrine-based dimers. European Journal of Medicinal Chemistry 46:9, pages 4336-4343.
Crossref
Crossref
Ignacio Lopez-Coviella, Tiffany J. Mellott, Aletta C. Schnitzler & Jan K. Blusztajn. (2011) BMP9 Protects Septal Neurons from Axotomy-Evoked Loss of Cholinergic Phenotype. PLoS ONE 6:6, pages e21166.
Crossref
Crossref
Annalena VenneriMichael F Shanks. (2011) Using MRI neuroimaging methods to detect treatment responses in Alzheimer’s disease. Neurodegenerative Disease Management 1:3, pages 235-243.
Crossref
Crossref
Ana Martinez, Carmen Gil & Daniel I. Perez. (2011) Glycogen Synthase Kinase 3 Inhibitors in the Next Horizon for Alzheimer's Disease Treatment. International Journal of Alzheimer's Disease 2011, pages 1-7.
Crossref
Crossref
María Isabel Fernández-Bachiller, Concepción Pérez, Gema C. González-Muñoz, Santiago Conde, Manuela G. López, Mercedes Villarroya, Antonio G. García & María Isabel Rodríguez-Franco. (2010) Novel Tacrine−8-Hydroxyquinoline Hybrids as Multifunctional Agents for the Treatment of Alzheimer’s Disease, with Neuroprotective, Cholinergic, Antioxidant, and Copper-Complexing Properties. Journal of Medicinal Chemistry 53:13, pages 4927-4937.
Crossref
Crossref
A. J. Larner. (2010) Transdermal rivastigmine for Alzheimer’s disease: skin deep or scratching the surface?. International Journal of Clinical Practice 64:5, pages 534-536.
Crossref
Crossref